daewoong nabota austria

Bio & Pharma Daewoong wins permission for Nabota in Argentina

South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...

Bio & Pharma Daewoong, Indonesia's IPB to co-research on primate

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it signed a contract with Indonesia's Bogor Agricultural University (Institut P...

Bio & Pharma Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combine...

Bio & Pharma Daewoong gets stem cell facility license in Indonesia

South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational...

Bio & Pharma Daewoong exports $92.4 mn Depot injection tech to UAE

South Korea's Daewoong Pharmaceutical announced on Monday that it exported its technology for clinical development and commercialization rights of i...

Bio & Pharma Daewoong Pharm set to export Envlo Tab to Russia, CIS

Daewoong Pharmaceutical, a leading South Korean pharmaceutical company will export its new diabetes drug Envlo Tab. (active ingredient:enavogliflozi...

Bio & Pharma Daewoong Pharma, Merck team up for AI tech for new drug

South Korea's Daewoong Pharmaceutical announced on Tuesday it signed with memorandum of understanding (MOU) with Merck Life Science to build an arti...

Bio & Pharma Daewoong Pharma's GER drug gets product OK from Mexico

South Korea’s Daewoong Pharmaceutical on Wednesday said its gastroesophageal reflux (GER) disease drug Fexuclue (active ingredient fexuprazan ...

Bio & Pharma Daewoong to develop eye drops for diabetic retinopathy

South Korea's Daewoong Pharmaceutical is venturing into the development of a product that can easily treat diabetic retinopathy in the form of ...

Bio & Pharma Daewoong gets patent of Nabota as migraine drug in US

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it has received a patent from the US Patent and Trademark Office for the use of...

Bio & Pharma Daewoong applies for approval of Envlo in Saudi Arabia

South Korea's Daewoong Pharmaceutical Co. announced on Friday that it has submitted an application for regulatory approval of its new diabetes treat...

Bio & Pharma Daewoong launches GERD treatment Fexuclu in Philippines

South Korea's Daewoong Pharmaceutical announced on Tuesday that it has launched the GERD treatment drug "Fexuclue" (active ingredient: Fexuprazan) i...

Bio & Pharma Daewoong's Nabota exceeds 600,000 customers in US

South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...

Bio & Pharma HanAll, Daewoong to develop Parkinson's treatment with US partner

South Korea's HanAll Biopharma Co. and Daewoong Pharmaceutical on Thursday said they concluded a contract with NurrOn Pharmaceuticals of the US on...

Energy Samsung Engineering, OMV sign agreement for modular project

South Korea's Samsung Engineering has partnered with global integrated energy company OMV for project collaboration. Samsung Engineering announced T...

Bio & Pharma Daewoong Pharmaceutical’s cumulative tech exports exceed $870 mn

South Korea’s Daewoong Pharmaceutical said on Friday that it had concluded three technology export agreements for new drugs and new drug candi...

Bio & Pharma Daewoong Pharma to build third botulinum toxin plant for $746 mn

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cos...

Bio & Pharma Daewoong to transfer techs for autoimmune disease to US pharma

South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...

Bio & Pharma Daewoong Pharma, UK firm to jointly develop autoimmune disease drug

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...

Bio & Pharma Daewoong wins approval for GERD treatment Fexuclu in Chile

South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...

Bio & Pharma Daewoong’s Nabota expands into Germany, Austria

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...

Bio & Pharma Daewoong Pharma's Fexuclue safe to use with aspirin: Clinical trials

Daewoong Pharmaceutical Co., a leading South Korean pharmaceutical company, has announced the successful completion of phase 1 clinical trials for...

Bio & Pharma Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exportin...

Bio & Pharma Korean court rules Daewoong poached Medytox’s botox strain

A South Korean court on Friday ruled in favor of Medytox Inc. in a civil lawsuit against its crosstown rival Daewoong Pharmaceutical Co. over the so...

Bio & Pharma Daewoong Pharma wins permission from Singapore for Nabota

South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin...

Bio & Pharma Medytox to sell off 2.2 mn shares of Daewoong's American partner Evolus

Medytox Inc. said in a regulatory filing on Wednesday that it is selling off approximately 2.19 million shares of Evolus, Daewoong Pharmaceutical's ...

Bio & Pharma Daewoong receives approval for its GERD drug Fexuclue in Ecuador

Daewoong Pharmaceutical said Friday that it has obtained marketing authorization from Ecuador's National Agency for Health Regulation, Control and S...

Bio & Pharma Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wri...

Bio & Pharma S.Korea's Daewoong Pharmaceutical to export tech to British company

South Korea's Daewoong Pharmaceutical has licensed a new drug candidate for idiopathic pulmonary fibrosis (IPF) to CS Pharmaceuticals (CSP) of the U...

Bio & Pharma S.Korea, Japan compete in gastroesophageal reflux drug market

South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical pr...